Not sure where to start? Take the 3-min clinical quiz.
See if you qualify →Hot flashes are sudden waves of heat, sweating, and flushing caused by changing estrogen signaling during perimenopause and menopause. They affect up to about 80% of women, often last 1 to 5 minutes, and may continue for years. Cooling steps, trigger control, nonhormonal prescriptions, and menopausal hormone therapy can all reduce symptoms for the right patient 1, 2.
What does a menopausal hot flash feel like?
Menopause hot flashes usually feel like a sudden rise in heat from the chest, neck, or face. The episode may come with flushing, sweating, chills afterward, a faster heartbeat, or a brief anxious feeling 1.
Common symptoms
- A sudden wave of heat in the upper body or whole body
- Redness or flushing of the face, neck, or chest
- Sweating, followed by chills as the body cools
- A racing heartbeat or brief feeling of panic
- Trouble focusing during the episode
Doctors often use the term vasomotor symptoms (VMS) because the blood vessels and the body’s heat-control system are involved. Symptoms can be mild, but for some people they are frequent enough to affect sleep, work, mood, and quality of life 3.
How night sweats differ
Night sweats are hot flashes that happen during sleep. They can soak clothing or sheets and may wake you up even after the heat wave is gone. Sleep disruption is one reason hot flashes can feel bigger than the few minutes they last 3.
How long a single hot flash lasts
A single hot flash often lasts 1 to 5 minutes, though some are shorter and some last longer 1. The bigger question is how long the life stage lasts: frequent hot flashes can continue for years, not just weeks.
Why does menopause cause hot flashes?
Estrogen helps regulate the brain’s thermostat. As estrogen levels fluctuate in perimenopause and fall after menopause, the brain may react to small body-temperature changes as if the body is too hot, triggering sweating and blood-vessel widening 3, 5.
The estrogen–thermostat connection
The hypothalamus is the part of the brain that helps control temperature. During the menopause transition, changing estrogen signaling can narrow the comfort zone for body temperature. When the brain senses heat, it may send signals that cause flushing, sweating, and a faster heart rate 5.
Newer nonhormonal drugs work through this same pathway. Fezolinetant (Veozah), a neurokinin 3 receptor antagonist, acts on brain signaling involved in hot flashes; in SKYLIGHT 1, fezolinetant reduced the frequency and severity of moderate-to-severe vasomotor symptoms compared with placebo, with adverse events and liver monitoring considered in treatment decisions 6.
Other conditions that mimic hot flashes
Not every heat wave is menopause. Thyroid disease, infection, low blood sugar, panic attacks, medication side effects, alcohol withdrawal, and some cancers can cause flushing or sweating 1. New, severe, one-sided, or unexplained symptoms deserve a medical review.
At what age do hot flashes start and stop?
Perimenopause often starts in the 40s, but timing varies. Hot flashes can begin before periods stop, peak around the final menstrual period, and continue into postmenopause for some people 2, 3.
Perimenopause through postmenopause
In the Study of Women’s Health Across the Nation, the median total duration of frequent vasomotor symptoms was 7.4 years. People whose symptoms began earlier in the menopause transition tended to have symptoms for longer 2.
Why some women have hot flashes into their 60s and 70s
Some women continue to have hot flashes well after the final menstrual period. Risk can be shaped by race and ethnicity, smoking, body weight, stress, anxiety, and how early symptoms began 2, 3. Persistent symptoms are common enough that treatment decisions should be based on current health, not age alone.
What triggers a hot flash?
Hot flash triggers differ from person to person, but heat, alcohol, spicy food, stress, smoking, and poor sleep are common patterns. Triggers do not cause menopause, but they can make an already sensitive thermostat fire more often 1, 3.
Common food and drink triggers
- Alcohol, especially close to bedtime
- Hot drinks, including coffee or tea
- Spicy foods
- Large meals that raise body heat
- Caffeine in people who notice a clear pattern
Environmental and lifestyle triggers
- Warm rooms or heavy bedding
- Tight clothing that traps heat
- Smoking or nicotine exposure
- Emotional stress
- Sleep loss, which can lower tolerance for symptoms
How to keep a trigger journal
For 2 weeks, write down the time of each hot flash, what you ate or drank, room temperature, stress level, and sleep quality. The goal is not to remove every possible trigger. It is to find your own repeat patterns so changes feel practical.
How can I reduce body heat during menopause without medication?
Body heat during menopause can often be reduced with cooling habits, sleep changes, weight management, and behavioral therapies. These steps are low risk for many people, but they may not be enough for moderate-to-severe symptoms 3, 4.
Layered clothing and cooling tools
- Dress in light layers that can be removed quickly.
- Use breathable sleepwear and sheets.
- Keep a fan, cooling pillow, or cold pack near the bed.
- Lower the bedroom temperature if possible.
- Sip cool water when an episode starts.
Weight, exercise, and smoking
Smoking is linked with more vasomotor symptoms, and weight can influence symptom burden in some studies 3. Regular movement supports sleep, mood, heart health, and weight maintenance, but exercise is not an instant hot-flash cure. If workouts trigger symptoms, cooler rooms, lighter clothing, and lower-intensity sessions may help.
Mind–body approaches: CBT, hypnosis, paced breathing
Cognitive behavioral therapy (CBT) does not stop estrogen changes, but it can reduce how disruptive hot flashes feel, especially when sleep and stress are involved. The North American Menopause Society lists CBT and clinical hypnosis as evidence-based nonhormonal options for vasomotor symptoms 4.
Paced breathing is safe for most people and may help with stress, but evidence for reducing hot-flash frequency is weaker than for CBT or hypnosis 4. It can still be useful as a calming tool during an episode.
What the evidence says about supplements
Many supplements are marketed for hot flashes, including soy isoflavones, black cohosh, evening primrose oil, and herbal blends. Evidence is mixed, product quality varies, and supplements can interact with medications or liver health 4. If you use them, tell your clinician.
What nonhormonal medications treat hot flashes?
Nonhormonal treatments for hot flashes include neurokinin-targeting drugs, certain antidepressants, gabapentin, clonidine, and oxybutynin. They can be helpful when hormone therapy is not wanted or not appropriate, but each has side effects and contraindications 4.
| Option | How it works | Evidence and key cautions |
|---|---|---|
| Fezolinetant (Veozah), neurokinin 3 receptor antagonist | Targets KNDy-neuron signaling in the brain’s temperature-control pathway | In SKYLIGHT 1, fezolinetant reduced moderate-to-severe vasomotor symptom frequency and severity compared with placebo; liver enzyme monitoring and drug-interaction review are part of safe use 6. |
| Elinzanetant (Lynkuet) | Targets neurokinin pathways involved in vasomotor symptoms | In OASIS 1 and 2, elinzanetant reduced vasomotor symptom frequency compared with placebo; sleepiness, headache, and regulatory-label precautions should be reviewed with a clinician 7. |
| Low-dose paroxetine, an SSRI | Affects serotonin signaling involved in temperature regulation | FDA-approved low-dose paroxetine mesylate is taken at bedtime in the product label; it can interact with tamoxifen and other medicines and may cause nausea, fatigue, or sexual side effects 8. |
| Other SSRIs/SNRIs | Affect serotonin and norepinephrine signaling | Options such as escitalopram and venlafaxine have trial evidence; risks include nausea, sleep changes, blood-pressure effects, and withdrawal symptoms if stopped suddenly 4, 9. |
| Gabapentin | Modulates nerve signaling and may help night symptoms | Can reduce hot-flash scores in trials, but dizziness, sleepiness, and balance concerns matter, especially at night 10. |
| Clonidine | Affects blood-vessel and nervous-system signaling | May help some people, but dry mouth, constipation, dizziness, and low blood pressure limit use 4. |
| Oxybutynin | Anticholinergic medicine that affects sweating pathways | Trial data suggest benefit for some patients; dry mouth, constipation, urinary issues, and cognitive concerns are important, especially with long-term anticholinergic exposure 11. |
Fezolinetant (Veozah) and elinzanetant (Lynkuet)
Fezolinetant (Veozah) is a neurokinin 3 receptor antagonist. Elinzanetant (Lynkuet) is another neurokinin-pathway medication studied for vasomotor symptoms. These options are hormone-free, but they still require a prescription review because liver health, medication interactions, pregnancy status, and side effects matter 6, 7.
Low-dose paroxetine and other SSRIs/SNRIs
Low-dose paroxetine is the SSRI with an FDA-labeled indication for moderate-to-severe vasomotor symptoms. Other SSRIs and SNRIs have evidence, but they are not right for everyone, especially people taking certain cancer therapies, other serotonin-active drugs, or medicines that raise bleeding risk 4, 8.
Gabapentin, clonidine, oxybutynin
Gabapentin may be most useful when night sweats and sleep disruption are major concerns, but sedation and dizziness can be limiting 10. Clonidine and oxybutynin can help selected patients, but side effects often shape whether they are a good fit 4, 11.
3-min quiz
Want help deciding what kind of menopause care fits?
Chia’s HRT for Women protocol includes oral estradiol plus progesterone IR when a licensed US provider finds hormone therapy clinically appropriate. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
Is hormone replacement therapy right for me?
Menopausal hormone therapy (MHT/HRT) is one of the most effective treatment categories for menopause hot flashes, but it is not right for every patient. The decision depends on symptom severity, uterus status, age, time since menopause, clot risk, breast-cancer history, liver disease, heart disease, stroke history, and personal goals 3, 12.
Estrogen alone vs. estrogen plus progesterone
Estrogen is the part of HRT that usually reduces hot flashes. If you still have a uterus, progesterone is commonly added to protect the uterine lining from estrogen-related overgrowth 12. If you do not have a uterus, estrogen alone may be considered in some cases.
Another FDA-approved hormone option is bazedoxifene plus conjugated estrogens, sometimes called a tissue-selective estrogen complex. It pairs estrogen with a selective estrogen receptor modulator instead of a progestogen, and its label includes treatment of moderate-to-severe vasomotor symptoms; risks and contraindications still require clinician review 13.
Delivery routes: pills, patches, gels, rings
HRT can be delivered as oral tablets, skin patches, gels, sprays, or vaginal rings, depending on the medication and goal. Systemic estrogen is used for whole-body symptoms like hot flashes, while low-dose vaginal estrogen is mainly used for vaginal and urinary symptoms, not whole-body hot flashes 12.
Benefits, risks, and who should avoid HRT
For many healthy patients younger than 60 or within 10 years of menopause onset, the benefit-risk balance of hormone therapy can be favorable when symptoms are bothersome 12. Risks may include blood clots, stroke, gallbladder disease, breast tenderness, bleeding changes, and breast-cancer considerations depending on the regimen and patient history 12, 14.
HRT is often avoided or used only with specialist input in people with a history of breast cancer, estrogen-sensitive cancer, unexplained vaginal bleeding, active or prior blood clots, stroke, heart attack, serious liver disease, or pregnancy 12. This is why a medical review matters even when symptoms clearly sound like menopause.
How can I get evaluated and treated at Chia?
Chia’s menopause care is fully online. For patients whose hot flashes may warrant hormone therapy, our HRT for Women protocol includes oral estradiol plus progesterone IR, compounded by US state-licensed 503A pharmacies and shipped to the patient’s door when prescribed.
Here is how it works: you complete a short health questionnaire, then a licensed US provider reviews your history and decides whether treatment is clinically appropriate. Dosing is provider-guided and adjusted over time. You can message your care team through the patient portal between visits. A prescription is never guaranteed.
| Chia option | Forms listed in Chia’s catalog | Good to know |
|---|---|---|
| HRT for Women protocol | Estradiol oral + progesterone IR | Used only after licensed-provider review; compounded by US 503A pharmacies; shipped to your door. |
| Eligibility quiz | Online quiz | A starting point for a clinician-reviewed visit; it does not guarantee a prescription. |
When should I see a clinician about hot flashes?
Hot flashes are worth discussing with a clinician if they disrupt sleep, mood, work, sex, or daily life. You should also be checked if symptoms are new after years without them, are paired with weight loss or fever, include chest pain or fainting, or happen with unusual bleeding 1, 3.
- Seek urgent care for chest pain, fainting, severe shortness of breath, or signs of stroke.
- Book a medical review for bleeding after menopause, unexplained weight loss, fever, or drenching sweats unrelated to typical hot flashes.
- Ask for help if night sweats are causing ongoing insomnia or daytime fatigue.
- Review your medications, thyroid history, cancer history, and clot risk before starting any prescription option.
Frequently asked questions
It usually feels like a sudden wave of heat in the face, neck, chest, or whole body. You may sweat, flush, feel your heart race, or feel chilled afterward. Some people also feel brief anxiety during the episode.
A single hot flash often lasts 1 to 5 minutes. The hot-flash stage can last much longer. In a large menopause cohort, frequent vasomotor symptoms lasted a median of 7.4 years, though some people have a shorter or longer course.
There is no single stop age. Many people improve in the years after the final menstrual period, but some continue into their 60s or later. Timing depends on when symptoms started, smoking, weight, stress, race and ethnicity, and health history.
Helpful options include dressing in layers, cooling the bedroom, avoiding personal triggers, limiting alcohol, not smoking, regular movement, CBT, clinical hypnosis, nonhormonal prescriptions, and hormone therapy when appropriate. The best choice depends on symptom severity and medical history.
Prescription options include fezolinetant, elinzanetant, low-dose paroxetine, some other SSRIs or SNRIs, gabapentin, clonidine, and oxybutynin. They can help selected patients, but side effects, liver health, blood pressure, sleepiness, drug interactions, and pregnancy status must be reviewed.
Hormone therapy can be appropriate for many healthy patients with bothersome hot flashes, especially when started before age 60 or within 10 years of menopause onset. It is not safe for everyone, including some people with breast cancer history, blood clots, stroke, heart disease, liver disease, unexplained bleeding, or pregnancy. Compounded drugs are not FDA-approved.
Yes. Chia offers an online HRT for Women protocol with oral estradiol plus progesterone IR when a licensed US provider finds it clinically appropriate. A prescription is not guaranteed. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health.
3-min quiz
Start a clinician-reviewed menopause visit
If hot flashes are affecting your sleep or daily life, Chia can review your health history online and assess whether the HRT for Women protocol is appropriate. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. You can also start through the eligibility quiz.
References
- 1.Cleveland Clinic. Hot Flashes: Symptoms, Causes, and Treatment, 2024.
- 2.Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Internal Medicine, 2015.
- 3.The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 2022.
- 4.The North American Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause, 2023.
- 5.Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of Body Temperature and LH Secretion by Hypothalamic KNDy Neurons: A Novel Hypothesis on the Mechanism of Hot Flushes. Frontiers in Neuroendocrinology, 2013.
- 6.Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated with Menopause (SKYLIGHT 1): A Phase 3 Randomised Controlled Study. The Lancet, 2023.
- 7.Simon JA, Kaunitz AM, Archer DF, Nappi RE, Kingsberg SA, Siddiqui E, Schmelter T, Stute P. Elinzanetant for Vasomotor Symptoms Associated with Menopause: OASIS 1 and OASIS 2 Phase 3 Randomized Clinical Trials. JAMA, 2024.
- 8.U.S. Food and Drug Administration. Brisdelle (paroxetine) Prescribing Information, 2013.
- 9.Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, Carpenter JS, Anderson GL, Larson JC, Ensrud KE, Reed SD, Newton KM, Sherman S, Sammel MD, LaCroix AZ. Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial. JAMA, 2011.
- 10.Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial. Menopause, 2008.
- 11.Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, Kuhle CL, Loprinzi CL. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized Clinical Trial. Journal of Clinical Oncology, 2020.
- 12.ACOG Committee Opinion No. 565. Hormone Therapy and Heart Disease. Obstetrics & Gynecology, 2013.
- 13.U.S. Food and Drug Administration. Duavee (conjugated estrogens/bazedoxifene) Prescribing Information, 2013.
- 14.Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA, 2002.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
Find what fits your body and your goals.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.

